Off-label · Investigational
PT-141 for men: the erectile research, the combination studies, and the off-label status
A careful reading of the male-sexual-function record — early erectile data, the central-plus-peripheral combination idea, and an approval that does not cover men.
In plain English
Here is the honest frame for PT-141 for men, stated before any detail: it is off-label and investigational — not approved, not established. Bremelanotide is approved only for premenopausal women with low sexual desire. In men, the research is early. Decades ago, an intranasal form produced erectile responses in men with erectile difficulty, and a small study combined it with a blood-flow drug for a stronger effect. That central-plus-peripheral idea is now back in early-stage development. Everything below reads that record carefully, and never as a recommendation or a protocol.
What does PT-141 do for men?
In early-phase research, PT-141 produced rapid, dose-dependent erectile activity in men with erectile dysfunction [1]. The mechanism is central — melanocortin MC4R/MC3R agonism in brain circuits of sexual motivation — not the peripheral vascular action of the more familiar erectile drugs [1][2]. That is the genuinely interesting part of the male story: a different mechanism, acting on desire and arousal rather than on penile blood flow.
The necessary qualifier rides alongside it. None of this is an approved use. The male and erectile evidence is early-phase and investigational, and a great deal of the most-cited male data is decades old. PT-141 for men is, today, a research question, not a treatment.
Is PT-141 approved for men?
No. Bremelanotide's only FDA-approved indication is HSDD in premenopausal women [6][11]. Use in men is off-label. A 2024 sexual-medicine-clinic abstract reported real-world off-label use of bremelanotide in men with sexual dysfunction, outside the approved indication — a conference report, a tier below peer-reviewed full text, and explicitly not an approval [13]. A Phase 2 program studying co-administration with a PDE-5 inhibitor for erectile dysfunction is the active development thread; it is investigational and ongoing, not a green light.
PT-141 nasal spray in the early development history
The earliest male erectile work used an intranasal route — a PT-141 nasal spray. Dose-escalation studies in men reported a statistically significant erectile response above 7 mg [1]. The intranasal form was then set aside: its pharmacokinetics (how the body absorbs and clears the drug) were too variable, and development moved to the subcutaneous route that became the approved product [6]. So the nasal spray belongs to the history, not the present — it is the form in which the male erectile signal first appeared, and the form that was abandoned for reliability. No current approved product is a nasal spray, and any "PT-141 nasal spray" sold today is unapproved research material.
Why is PT-141 being studied with a PDE-5 inhibitor?
Because the two mechanisms are complementary rather than competing — central desire-and-arousal signaling on one side, peripheral blood flow on the other. An early study co-administered low-dose intranasal PT-141 with sildenafil in men with erectile dysfunction and examined the safety and erectile pharmacodynamics of pairing a central melanocortin agonist with a peripheral PDE-5 inhibitor; the combination produced an enhanced erectile response [7]. That foundational combination-pharmacology result is the seed of the current approach.
A later trial reported a salvage benefit in PDE-5-inhibitor non-responders. We cite it with a flag: an Expression of Concern was issued for that 2008 study in 2023, so its findings should be treated as disputed [9]. We surface the result and the concern together, because honesty about the evidence base includes honesty about which parts of it are contested.
PT-141 versus PDE-5 inhibitors: a central-plus-peripheral comparison
The research does not frame PT-141 and PDE-5 inhibitors as better-or-worse; it frames them as different, and increasingly as partners. A PDE-5 inhibitor acts peripherally on penile vascular smooth muscle to improve erectile blood flow. PT-141 acts centrally, on the melanocortin circuits of sexual motivation [1][2]. A review of novel emerging erectile-dysfunction therapies placed melanocortin agonists such as bremelanotide among the investigational, centrally acting approaches — a category distinct from the peripheral PDE-5 class [10].
That distinction is precisely why the two have been studied together rather than against each other [7][10]. Where a PDE-5 inhibitor improves the plumbing, a central melanocortin agonist may address the wanting — and an ongoing Phase 2 co-administration program is testing exactly that pairing in non-responders. This is a research comparison, not a recommendation, and neither the combination nor the male use is approved.
A note on what this means for the reader
PT-141 for men is an active and genuinely interesting research story, and it is also an unapproved one. The central mechanism is real, the early erectile signal is real, the combination logic is sound, and none of it amounts to an established treatment a reader should pursue. We report the studies; we recommend no dose, no route, and no source. The tolerability facts that apply to anyone exposed to bremelanotide — including the cardiovascular contraindication — are read in full on the PT-141 side effects page, and the studies behind these findings are listed in one place.